00:35 , Oct 21, 2017 |  BioCentury  |  Product Development

Naked ambition

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without...
07:00 , Apr 24, 2014 |  BC Innovations  |  Targets & Mechanisms

Mired in miR-25

Preclinical data showing that microRNA-25 inhibition can help treat heart failure directly contradict a 2013 paper suggesting that decreased levels of the miRNA provoke the condition. 1,2 Although the new study shows that blocking microRNA-25...
07:00 , Jun 4, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia; myocardial infarction (MI) MicroRNA-92a (miRNA-92a) A study in mice and in cell culture suggests that inhibiting miRNA-92a could help...